Knopp Biosciences LLC, a drug discovery and development company, announced yesterday that it has commenced phase two dose-ranging clinical trial of oral dexpramipexole in moderate-to-severe eosinophilic asthma.
The company has started recruitment of patients and the first patient has been enrolled. It expects to report top-line data from this trial in the second half of 2020.
This 12-week biomarker study is planned to randomise around 100 patients with eosinophilic asthma to investigate the eosinophil response to three different doses of oral dexpramipexole. The primary result measure of this randomised, double-blind, placebo-controlled study is the change in blood absolute eosinophil count from Baseline to Week 12. The secondary outcome measures include changes in pre-bronchodilator FEV1 and asthma control outcomes (ACQ-7 questionnaire) from baseline to week 12.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients